Live Analyst Rating Changes 8895 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/James Gordon CFA
BARC
James Gordon CFA
Barclays
Wall Street Analyst
Not yet ranked — too few measurable calls.
—
Success Rate
—
Average Return
— vs benchmark
🔒 3-year track record is Pro. Showing 1-year — upgrade.

Rating Distribution

60 Buy 32 Hold 24 Sell
James's Stock Coverage 13 ratings · 2026-07-16
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return
GB:GSK
GlaxoSmithKline
 Jul 14, 2026 SELL Hold
-1.1% avg upside
25 analysts
$1900.00
0.92% Downside
 ·
SE:SOBI
Swedish Orphan Biovitrum AB
 Jul 03, 2026 BUY Strong Buy
-11.4% avg upside
7 analysts
$530.00
16.27% Upside
 ·
GB:0MGB
Genmab A/S
 Jul 02, 2026 BUY Buy
+15.2% avg upside
22 analysts
$2500.00
32.83% Upside
 ·
CH:SDZ
Sandoz Group Ltd
 Jul 01, 2026 BUY Buy
+2.5% avg upside
11 analysts
$81.00
24.95% Upside
 ·
CH:GALD
Galderma Group AG
 Jul 01, 2026 BUY Strong Buy
+10.4% avg upside
10 analysts
$200.00
20.02% Upside
 ·
GB:AZN
AstraZeneca
 Jun 30, 2026 BUY Strong Buy
+17.9% avg upside
26 analysts
$16500.00
31.32% Upside
 ·
CH:NOVN
Novartis AG
 Jun 30, 2026 HOLD Buy
-11.3% avg upside
31 analysts
$120.00
1.57% Downside
 ·
GB:0QW0
arGEN X
 Jun 25, 2026 BUY Strong Buy
-20.5% avg upside
24 analysts
$900.00
18.95% Upside
 ·
GB:HIK
Hikma Pharmaceuticals
 Jun 23, 2026 SELL Strong Buy
+54.7% avg upside
8 analysts
$1350.00
9.75% Downside
 ·
CH:ROP
Roche Holding AG
 May 26, 2026 BUY Buy
+1.0% avg upside
23 analysts
$410.00
24.23% Upside
 ·
GB:0QIU
Novo Nordisk
 May 19, 2026 HOLD Buy
+27.3% avg upside
29 analysts
$300.00
6.55% Downside
 ·
FR:SAN
Sanofi
 Apr 23, 2026 HOLD Strong Buy
+29.4% avg upside
30 analysts
$85.00
11.50% Upside
 ·
NL:LKFT
Galapagos
 Jan 23, 2025 SELL Sell
+103.4% avg upside
16 analysts
$22.00
14.59% Downside
 ·
🔒 8 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
James Gordon CFA — Frequently Asked Questions
How accurate are James Gordon CFA's stock ratings?
Based on the calls 13Foresight could measure, about —% of James's ratings were profitable over a one-year hold, with an average return of —% per rating. We score every analyst the same way, from historical prices.
How is James ranked on 13Foresight?
James Gordon CFA is currently ranked unranked . Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does James cover?
James most recently has ratings on GB:GSK, SE:SOBI, GB:0MGB, CH:SDZ, CH:GALD, GB:AZN, CH:NOVN, GB:0QW0, GB:HIK, CH:ROP, GB:0QIU, FR:SAN and 1 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.